StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Tablet
Marketer
Sarvagunaushdhi Pvt Ltd
Salt Composition
Glimepiride (2mg) + Metformin (500mg) + Voglibose (0.2mg)
Overview StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Tablet
Diabetics utilizing the triple-combination therapy tablet, StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg, benefit from its anti-diabetic properties. This medication, prescribed for adult type 2 diabetes, effectively manages blood glucose. Administer this medication with food, consistently at the same time daily for optimal efficacy. Dosage adjustments are determined by your physician based on your blood sugar response. Continuous use is crucial; discontinuation without medical consultation risks elevated blood sugar, potentially leading to kidney complications, vision impairment, neuropathy, and limb loss. Remember, this medication complements a holistic approach including diet, exercise, and weight management as directed by your doctor. Commonly reported is hypoglycemia (low blood sugar), characterized by sweating, dizziness, headaches, and tremors. Carrying readily available glucose sources, like sugary snacks or juice, mitigates this risk, as does maintaining regular meals. Alcohol consumption should be limited due to its potential to exacerbate hypoglycemia. Other potential side effects include altered taste, nausea, diarrhea, abdominal discomfort, headache, swelling (edema), blurred vision, bone fractures, upper respiratory infections, and weight gain. This medication is contraindicated for type 1 diabetes, diabetic ketoacidosis, and severe hepatic or renal impairment. Patients with a history of heart disease should inform their physician before commencing treatment. Pregnant or lactating individuals require medical consultation prior to use. Regular blood glucose monitoring, along with periodic blood tests to evaluate blood cell counts and liver function, are recommended.
Uses of StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Tablet
Managing type 2 diabetes
Major Benefits of StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Tablet:
Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. This StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg tablet should be taken on an empty stomach.
Common Side effects of StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Tablet:
- Nausea
- Diarrhea
- Abdominal pain
- Hypoglycemia (low blood glucose level)
- Loss of appetite
How to use StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Tablet:
Consume this medication precisely as your physician directs, adhering to the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Tablet should be taken on an empty stomach.
How StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Tablet works:
Each StayHappi tablet (2mg glimepiride, 500mg metformin, 0.2mg voglibose) combines three medications to manage diabetes.
SAFETY ADVICE
AlcoholUNSAFE
Consuming alcohol while taking StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Tablet poses a safety risk.
PregnancyCONSULT YOUR DOCTOR
The use of StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg tablets during pregnancy may pose risks. While human research is scarce, animal studies indicate potential harm to a developing fetus. A physician will assess the advantages against possible risks prior to prescribing this medication. Seek medical advice before using this drug.
Breast feedingCONSULT YOUR DOCTOR
The use of StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Tablet while breastfeeding is likely inadvisable. Available evidence from human studies indicates potential transfer of the medication into breast milk, posing a possible risk to the infant.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.
KidneyUNSAFE
The use of StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg tablets is likely unsafe for individuals with kidney impairment and should be omitted. Medical advice is necessary. Furthermore, this medication is unsuitable for patients experiencing severe kidney disease.
LiverCAUTION
Patients with liver disease should use StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Tablets cautiously, potentially requiring dose modification. Individuals with mild to moderate liver impairment typically begin with a low dose; however, this medication is unsuitable for those with severe liver disease. Medical advice is essential.
What if you forget to take StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Tablet :
Should you forget a dose of StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Tablet, administer it at your earliest convenience. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About StayHappi Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Tablet
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Medication |
3,018 People bought this recently